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ABSTRACT
Pulmonary graft-versus-host disease (p-GVHD) is a serious complication after allogeneic stem cell transplanta-
tion (allo-SCT) of high morbidity and high mortality. We characterized breathing patterns and pulmonary func-
tion changes in correlation to lung histopathology and survival by using a well-established murine model of p-
GVHD. Lethally irradiated B6D2F1 mice received SCT from either syngeneic B6D2F1 or allogeneic C57BL/6
animals. Within 6 weeks, severe p-GVHD developed in allogeneic recipients characterized by progressive inter-
stitial, alveolar, peribronchial, and periluminal inflammatory cell infiltration, whereas in syngeneic recipients lung
histology remained normal. Allogeneic recipients demonstrated decreased minute ventilation (MV), reduced
peak inspiratory and expiratory flow rates as early as 1 week after SCT. In addition, allo-SCT resulted in restric-
tive pulmonary function changes as early as 7 days after transplantation and in progressive airflow obstruction
within 6 weeks. Decreased breathing abilities and pulmonary function changes of allogeneic recipients were as-
sociated with increased mortality and the severity of acute graft-versus-host disease (aGVHD). These findings
show that p-GVHD can be characterized by changes in pulmonary function and functional respiratory insuffi-
ciency. Furthermore, our data strengthen the understanding, that the lung is a critical target organ of aGVHD.
 2008 American Society for Blood and Marrow Transplantation
KEY WORDS
Allogeneic stem cell transplantation  Lung  Graft-versus-host disease  Pulmonary func-
tion  Restrictive  ObstructiveINTRODUCTION
Allogeneic (allo-) stem cell transplantation (SCT)
is an important therapeutic option for a number of
malignant and nonmalignant diseases. However, the
utility of allo-SCT is limited by severe complications,
including the development of acute graft-versus-host
disease (aGVHD) and pulmonary injury. Historically,
approximately 50% of all pulmonary infiltrates seen
after SCT have been secondary to infection, but the
judicious use of broad-spectrum antimicrobial pro-
phylaxis in recent years has tipped the balance of
pulmonary complications from infectious to noninfec-
tious causes [1]. In addition to periengraftment
syndrome (PERDS), a noninfectious, alloantigen-
independent injury occurring around the time of
engraftment [2], various forms of noninfectious,alloimmune-mediated acute lung injuries can develop
within the first few months after allo-SCT, such as
interstitial and alveolar pneumonitis, perivascular lym-
phocytic inflammation, and lymphocytic bronchiolitis,
and are rarely seen in patients after autologous SCT
[3-8]. Themost dramatic clinical course has been asso-
ciated with noninfectious interstitial pneumonitis clas-
sically defined as idiopathic pneumonia syndrome
(IPS) [4]. IPS occurs in 5% to 25% of patients after
allo-SCT, depending upon conditioning toxicity, spe-
cifically the use of lethal total body irradiation (TBI),
donor source, and the degree of antigenic mismatch
between donor and recipient, and has a mortality of
approximately 80% [9,10]. Animal models showed
that the underlying pathophysiology is complex, and
involves conditioning-related cytotoxic effects [9],
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cruitment of both donor cytotoxic and helper T cells
and accessory cells into the lung [13-20]. Therefore,
concurrent understanding grows, that IPS and other
overlapping forms of acute noninfectious lung injury
after allo-SCT resemble forms of acute pulmonary
GVHD (p-GVHD) and p-GVHD-related toxicity.
Various models of acute lung injury mirroring
acute p-GVHD after allo-SCT have been described
[14,15,17,20,21]. We extensively studied the underly-
ing mechanisms of donor leukocyte recruitment into
the lung using a murine model of allo-SCT, in which
donor cell alloreactivity developed across MHC class
I, MHC class II, and minor antigen mismatches, and
in which p-GVHD was reliably induced within 3 to
6 weeks after transplantation [13,17-19]. In these stud-
ies as well as others, alterations in histopathology,
pulmonary vascular endothelial cell integrity, and the
cellular and cytokine content of bronchoalveolar la-
vage fluid correlate very well with that seen in patients
[3,4,13-16,22,23], and have been the hallmark of ex-
perimental lung injury, but pulmonary function tests
(PFT) have been only sporadically used to determine
the extent of disease [14,16,24-26]. Especially, no serial
analysis of breathing characteristics has yet been per-
formed to assess the kinetics of pulmonary impairment
incurred during the clinical course post-allo-SCT.
In the present study, we determined the kinetics of
SCT-related changes of breathing patterns, including
respiratory rate (RR), tidal volume (TV), minute venti-
lation (MV), peak inspiratory flow (PIF), and peak
expiratory flow (PEF), as well as alterations of lung vol-
umes and forced expirationmaneuvers in ourpreviously
characterized allo-SCTmodel [17]. Changes in pulmo-
nary function were correlated to lung histopathology
and to survival. As expected, allo-SCTresulted in severe
p-GVHD development, which was clinically paralleled
by respiratory insufficiency and increased mortality.
MATERIALS AND METHODS
Mice and Stem Cell Transplantation
Female C57BL/6 (H-2b) and B6D2F1 (H-2bxd)
mice were purchased from Charles River Laboratories
(Sulzbach, Germany) and acclimatized in our animal
facility for at least 1 week before the experiments. An-
imals were between 10 and 20 weeks old at the time of
SCT. All animal experiments were approved by the lo-
cal institutional animal committee of the University of
Regensburg, and were in accordance with German an-
imal protection laws.
Mice were transplanted according to a standard
protocol as previously described [17]. On the day of
SCT, B6D2F1 recipient mice received lethal TBI
delivered in 2 fractions 3 hours apart to reduce gastro-
intestinal toxicity. TBI was given by a linear accelera-
tor at a dose rate of 150 cGy/min. A total dose of 13 Gywas given to animals used to assess lung volumes,
forced ventilation parameters, and histopathology,
and 12 Gy were given to those animals used for weekly
measurements of breathing patterns within in the same
animal up to 12 weeks after allo-SCT. TBI was
followed by the infusion of cell mixtures of 5  106
bone marrow cells supplemented with 1, 3, or 6 
106 splenocytes from either syngeneic (B6D2F1) or al-
logeneic (C57BL/6) donors. Transplanted mice were
housed in microisolator cages and received autoclaved
chow, bedding, and hyperchlorinated water ad libitum.
Clinical GVHD and Survival
Survival was monitored daily until day 184 after
SCT, and clinical GVHD scores were assessed weekly
by a scoring system incorporating 5 clinical parameters:
weight loss, posture (hunching), mobility, fur texture,
and skin integrity, as described previously [15]. Each
parameter was graded between 0 and 2. Once an animal
reached a cumulative score $6.5 or a weight loss of
.30% of the initial weight before SCT, the mouse
was sacrificed and counted as a GVHD-related death.
Measurement of Lung Function
Assessment of pulmonary function was performed
using a Buxco lung function analysis system (BUXCO
Electronics, Troy, NY) consisting of a pulmonary func-
tion test/forced maneuvers analyzer (SFT3840) plus
pressure panel for mouse maneuvers (AUT6100), an
unrestrained whole-body plethysmograph (WBP)
(SFT3812), and an anesthetized mouse—PFT plethys-
mograph (PLY3112). Data acquisition and analysis was
done using BioSystem XA software (SFT3850).
The use of the unrestrained WBP allows the re-
peatedmeasurementof respiratorypatterns in conscious,
freely moving animals at multiple time points. Measure-
ments were performed according to the manufacturer’s
on-site instruction and protocol. Each animal was tested
individually. Prior to testing, the mouse was allowed to
acclimatize to the chamber for at least 2 minutes until
no signs of distresswere evident and the animal appeared
relaxed and calmly breathing. Data acquisition was per-
formed over a time period of 2 to 3 minutes, during
which the spontaneously breathing animal moved freely
in the chamber. In vivo parameters of breathing obtained
included: TV (mL), RR (breaths per minute), MV (mL/
min), PIF (mL/sec) andPEF (mL/sec). For each individ-
ual mouse this test was repeated 3 times in sequence and
values were averaged. For kinetics, animals were ana-
lyzed before SCT and then weekly thereafter until day
184. Data after SCT were presented in relation to pre-
SCT values of the same animal by using the formula:
% of pre-SCT value 5 measured value after SCT/pre-
SCT value  100.
The anesthetized mouse - PFT plethysmograph,
allows the assessment of lung volumes and forced
1006 S. Miklos et al.ventilation parameters. Measurements were per-
formed according to the manufacturer’s on-site in-
struction and protocol. To perform these tests,
animals were anesthetized by the intraperitoneal injec-
tion of ketamine hydrochloride (50 mg/kg) and mede-
tomidine hydrochloride (0.33 mg/kg). The trachea
was dissected, cleaned of surrounding tissue, and can-
nulated with a 17- to 19-gauge cannula, depending on
the trachea size and the size of the mouse. Animals
were placed into the chamber and mouse lungs were
connected over the tracheal cannula through a port in
the chamber wall to a built-in ventilator. Sedation was
ensured to be deep enough to prevent spontaneous
breathing against passive ventilation before tests were
performed. Fast flow volume measurements were
done to assess air outflow obstruction, and quasistatic
pressure volume measurements were performed to
assess lung volumes. Parameters included in the analysis
were vital capacity (VC,mL), forced vital capacity (FVC,
mL), forced expiratory volume (FEV, mL) at 20, 50, 100,
and 200milliseconds, forced expiratory flow (FEF,mL/
sec) at 25% of expiration, and chord complicance at
0-10 cm H2O (Cchord, mL/cm H2O). As animals
were sacrificed following these procedures, fast flow
volume measurements and quasistatic pressure volume
measurements could not be repeatedly performed for
kinetics within the same animal, but required different
animals for data acquisition at different time points after
SCT. Measurements were conducted 7 and 42 days af-
ter transplantation, and values were presented in rela-
tion to values obtained from comparably aged naı¨ve
animals by using the formula: % of naive 5 measured
value after SCT/value measured in naive  100.
Semiquantitative Histopathology of Lung,
Gastrointestinal Tract, and Liver
On days17 and142 after transplantation, animals
were sacrificed for histopathologic analysis. Lungs
were removed, fixed in 4% paraformaldehyde dis-
solved in PBS, transferred into 70% ethanol after 48
hours, paraffin-embedded, and then 4-mm sections
were obtained. Hematoxylin-eosin-stained lung
sections from individual mice were coded without ref-
erence to mouse type and prior treatment and inde-
pendently examined to establish an index of injury.
Analysis was performed by light microscopy (Axioskop
2 plus, Carl Zeiss GmbH, Jena, Germany). Photomi-
crographs were acquired with the AxioCam HRc
(Carl Zeiss GmbH) and processed with AxioVision
Release 4.6.3 (Carl Zeiss GmbH). Lungs were
evaluated for the presence of periluminal infiltrates
or parenchymal pneumonitis using a semiquantitative
scoring system as described previously [15,19].
Detailed gastrointestinal (GI) tract and liver histo-
pathologic analyses were performed in a blinded fash-
ion on days 17 and 142 after transplantation, as
previously described [16,27].Western Immunoblotting for Surfactant Protein A
(SP-A)
Lung samples were homogenized in lysis buffer
plus protease inhibitors (Tris-buffered saline [2])1
EDTA pH 8, leupeptin [0.5 mg/mL], vanadate
[0.5 mM], natriumfluoride [0.2 mM], aproptinin
[2 mg/mL], beta-glycerolphosphate [10 mM], Na-
pyrophosphate [0.2 mM], phenylmethylsulfonylfluor-
ide [1 mM], nonidet [1%]) and centrifuged at 13,000
U/min for 15 minutes. Twenty-five micorgrams of
protein extracts were separated on 15% SDS-poly-
acrylamide gels and transferred onto a nitrocellulose
membrane (Schleicher & Schell, Dassel, Germany).
Nonspecific binding was blocked using Tris-buffered
saline/0.1% Tween 20 (TTBS) with 5% bovine serum
albumin for 1 hour at room temperature. Subse-
quently, the blot was incubated with antibodies against
surfactant protein A (1:2000; Chemicon, Chandlers
Ford, UK) and actin (1:2000; Sigma-Aldrich, Tauf-
kirchen, Germany) for 1 hour. Blots were washed in
TTBS and incubated with peroxidase-conjugated
goat-anti-rabbit antibody (1:2000, Dako, Glostrup,
Denmark) for 30 minutes. Bands were visualized using
chemiluminescence (ECL Western Blotting Analysis
System and ECL Hyperfilm, Amersham Biosciences,
Piscataway, NJ).
For quantification, blots were scanned (HP Desk-
jet F4180, Hewlett-Packard, Palo Alto, CA) and ana-
lyzed using the public domain NIH image program.
Statistical Considerations
All values are expressed as mean6 SEM. Statistical
comparisons between groups were completed using
the parametric independent sample t test if n$ 5 or us-
ing the Mann-Whitney test if n\ 5. For survival and
cumulative incidence of pulmonary function changes,
actuarial curves were obtained by Kaplan-Meier
method and statistically compared using the log rank
test. The P values were 2 sided, and a significance level
of a 5 .05 was used.
RESULTS
Lung Injury, Survival, and Clinical GVHD
Lethally irradiated B6D2F1 mice received SCT
with 5  106 bone marrow and 6  106 splenocytes
from either syngeneic (B6D2F1) or allogeneic (C57Bl/
6) donors as described inMaterials andMethods. Lung
histopathology was obtained on day 17 and day 142
after transplantation, and pulmonary injury was
determined by using a well-established scoring system
[15,19]. Allogeneic recipients showed progressive lung
injury from day 17, consistent with the development
of interstitial pneumonitis, perivascular lymphocytic
inflammation, and lymphocytic bronchiolitis until
week 6, whereas lungs of mice receiving syngeneic
SCT maintained normal histology (Figure 1a-b).
Lung Function Changes in Pulmonary GVHD 1007Figure 1. Lung injury, survival, and clinical GVHD. Lethally irradiated B6D2F1 mice received SCT with 5  106 bone marrow and 6  106
splenocytes from either syngeneic (B6D2F1) or allogeneic (C57Bl/6) donors as described in Materials and Methods. (A-B) Pulmonary injury
was determined on days 17 and 142 after SCT by using a well-established scoring system and by histopathology; *P\ .05 (syngeneic [white
bar] versus allogeneic [black bar]). Animals were monitored daily for (C) survival and weekly for (D) GVHD clinical scores and (E) weight.
*P\ .05 (syngeneic [dotted line, open triangles] versus allogeneic [solid black line, filled squares]). Data are presented as mean6 SEM. Survival
data are combined from 2 independent and comparable experiments; n (syngeneic) 5 8, n (allogeneic) 5 17 for survival. Histopatholoy data at
week 1 are combined from 2 independent experiments (n [syngeneic] 5 7, n [allogeneic] 5 8) and at week 6 are combined from 3 independent
experiments (n [syngeneic] 5 7, n [allogeneic] 5 16). *P\ .05.These findings were confirmative of our previous stud-
ies using the same model of p-GVHD, in which we
characterized the histopathologic changes and alter-
ations in bronchoalveolar lavage cellularity and cyto-
kine or chemokine expression [13,17-19].
Survival and the severity of clinical GVHD were
monitored over 84 days after transplantation. Because
of radiation conditioning toxicity, syngeneic recipients
demonstrated minor changes in weight loss, fur tex-
ture, and mobility by week 1, but then rapidly regained
body weight and completely recovered clinically. All of
these animals survived (Figure 1c-e). In contrast,
allogeneic recipients developed severe weight loss
and clinical GVHD symptoms after SCT, and two-
thirds of the animals succumbed by 12 weeks after
allo-SCT, with the highest mortality rates between
week 3 and week 6 (Figure 1c-e).
Changes in Minute Ventilation
The use of an unrestrained WBP to repeatedly
assess basic breathing parameters in the same animal
allowed us to test changes in MV, TV, RR, PIF, andPEF in surviving animals over the entire observation
period of 12 weeks after transplantation.
MV is defined as the volume of gas that moves in
and out of the lungs in 1 minute and is calculated by
multiplying the exhaled TV by the RR. In syngeneic
recipients MV dropped within the first 2 weeks after
SCT to an average of 84% of pre-SCT values on day
114 and then went back to normal range values by
week 5 (Figure 2a). TV was not decreased early after
transplantation. Moreover, it increased over time in
parallel to the weight gain observed in these animals
(Figure 2b), and at the same time RR were decreased
to maintain stable MV (Figure 2c). In contrast, alloge-
neic recipients demonstrated a dramatic decrease in
MV by day 17 down to 57% of pre-SCT values, that
persisted over time, and at week 12 MV only partially
recovered to 73% of pre-SCT values in surviving ani-
mals (Figure 2a). In addition, TV and RR dropped
significantly when compared to recipients of syngeneic
SCT (Figure 2b-c). We then chose to assess cumula-
tive incidences of severe reduction of MV, defined as
MV #50% of pre-SCT values and of moderate to
severe reduction of MV, defined as MV #60% of
1008 S. Miklos et al.Figure 2. Changes in breathing patterns. Lethally irradiated B6D2F1 mice received SCT with 5  106 bone marrow and 6  106 splenocytes
from either syngeneic (B6D2F1, dotted line, open triangles) or allogeneic (C57Bl/6, solid black line, filled squares) donors as described in Ma-
terials andMethods. Respiratory patterns were measured weekly by whole-body plethysmography in conscious, freely moving animals. To com-
pare changes in breathing patterns of allogeneic recipients with syngeneic controls the following parameters were assessed: (A) minute ventilation
(MV), (B) tidal volume (TV), (C) respiratory rate (RR), (D) cumulative incidences of MV#50% of pre-SCT, (E) peak inspiratory flow (PIF), (F)
peak expiratory flow (PEF), (G) cumulative incidences of PIF#70%of pre-SCT, (H) cumulative incidences of PEF#50%of pre-SCT. For both
syngeneic and allogeneic recipients, data shown are expressed as % of baseline values. In addition, changes in allogeneic recipients are demon-
strated as % of syngeneic (A-C, E-F). Data are presented as mean6 SEM and are combined from 3 independent comparable experiments; initial
n 5 13 to 25 per group, minimal n at each time point $5; *P\ .05; **P\ .001.pre-SCT values. These cut-off levels were chosen ac-
cording to the observed MV changes (Figure 2a), and
severe reduction of MV was defined as the next 10%
interval below the lowest average, whereas moderatereduction was defined as the next 10% interval above
the lowest average of MV. Syngeneic recipients never
developed a moderate or severe reduction in MV. In
contrast, by day 144 63.3% of allogeneic recipients
Lung Function Changes in Pulmonary GVHD 1009Figure 3.Changes in minute ventilation (MV) and peak inspiratory flow (PIF), but not peak expiratory flow (PEF), are associated with increased
mortality after allogeneic SCT. (A-C) Increased mortality in allogeneic recipients given 5  106 bone marrow and 6  106 splenocytes was as-
sociated (A) with MV #50% (black solid line) versus MV .50% (black dotted line), (B) PIF #70% (black solid line) versus PIF .70% (black
dotted line), but (C) not with reductions in PEF (PEF #50% [black solid line] versus PEF .50% [black dotted line]). (D) Overall survival in
allogeneic recipients was directly related to clinical GVHD severity (GVHD$5: black solid line; GVHD\5: black dotted line). (E-G) Clinical
GVHD scores $5 were associated with (E) MV #50% (black solid line) versus MV .50% (black dotted line), (F) PIF #70% (black solid line)
versus PIF.70% (black dotted line), but (G) not with reductions in PEF (PEF#50% [black solid line] versus PEF .50% [black dotted line]).
Data presented are combined from 3 independent comparable experiments; total n 5 25; *P\ .05; **P\ .001.developed a severe reduction in MV (P 5 .001;
Figure 2d) and 90.7% had a moderate reduction in
MV (P 5\.001; data not shown).
Changes in PIF and PEF
Next, we analyzed whether changes in inspiration
or expiration flow rates occurred along with the ob-
served alterations in RR and TV. PIF was not affected
after syngeneic SCT, andwas significantly diminuished
in allogeneic recipients when compared to pre-SCT
values or to syngeneic controls (Figure 2e). Even
more evident than the changes of PIF in allogeneic
recipients, PEF dropped to 56% of pre-SCT values
within the first week after allo-SCT and stayed reduced
at levels\70% of pre-SCT values throughout the fol-
low-up period (Figure 2f). In syngeneic recipients, PEF
values were reduced by 22% within the first 2 weeks
after SCT and then remained stable (Figure 2f). PEF
in allogeneic recipients was significantly reduced at
all times when compared with animals after syngeneic
SCT. We then analyzed the cumulative incidences of
severe reduction of PIF, defined as PIF #70% of pre-
SCT values and of severe reduction of PEF, defined
as PEF #50% of pre-SCT values. These cutoff levels
were chosen according to the observed PIF and PEF
changes (Figure 2e-f), and severe reduction of PIF or
PEF was defined as the next 10% interval below the
lowest average of PIF and PEF, respectively. Althoughsyngeneic recipients did not develop either severe
reductions of PIF or PEF (Figure 2g-h), severe reduc-
tions of PIF (P\ .001) and PEF (P\ .001) were seen in
73.3%and 80.7%, respectively, of allogeneic recipients
by day 1 51.
Increased Mortality in Animals Is Associated with
Reductions in MVor PIF but not PEF
As allogeneic recipients developed significant
changes in MV, PIF and PEF, we next tested, whether
impaired MV, PIF, or PEF correlated with the in-
creased mortality being observed between weeks 3
and 6 after allo-SCT with 5  106 bone marrow and
6  106 splenocytes. The strongest association with
decreased survival was seen for MV; 88.2% of animals,
in which MV deteriorated to #50% of pre-SCT
values, died until day 144, and all of these animals
died by day 1100. In contrast, of those animals, in
which MV remained better than 50% of pre-SCT
values, 90% lived until the end of the observation
period (P\ .001) (Figure 3a). The development of se-
vere reduction in PIF also correlated with increased
mortality after allo-SCT (day 84: 91.2% versus 12.5%;
P 5 .002) (Figure 3b), whereas changes in PEF did not
(day 84: 76.5% versus 37.5%; P 5 0.227) (Figure 3c).
One of the most important factors affecting sur-
vival after allo-SCT is the development of aGVHD.
Therefore, we then analyzed if aGVHD severity
1010 S. Miklos et al.correlated with mortality and changes in breathing
patterns. All animals developing maximum aGVHD
$5 died by day163, and 70% of animals with a maxi-
mum aGVHD score\5 survived until day 184 (P 5
.017; Figure 3d). All recipients of allo-SCT with
aGVHD scores $5 developed severe reductions of
MV until day 144 and of PIF until day 151, respec-
tively, whereas until the end of the observation period
MV and PIF values were severely decreased in only
20% and 30% of animals with aGVHD scores \5
(Figure 3e-f). In contrast, severe impairment of PEF
was not associated with aGVHD severity, as severe re-
ductions of PEF were found in 70.0% and 77.7% of
mice, which had maximum aGVHD scores \5 and
$5, respectively (Figure 3g).
We next wanted to know whether the observed
changes in breathing patterns were because of intrinsic
lung pathology or whether they rather reflected the
clinically impaired general state of health after allo-
SCT as indicated by severe clinical GVHD scores
and weight loss. To address this question, we per-
formed T cell titration experiments, in which animals
received increasing numbers of donor spleen cells
(1  106, 3  106, 6  106) to induce different degrees
of GVHD severity, whereas numbers of bone marrow-
derived stem cells were kept unchanged. As depicted in
Table 1, elevated clinical GVHD scores directly
related to the transplanted T cell dose both at week 1
(2.8 6 0.2 versus 3.5 6 0.0 versus 4.0 6 0.2) and
week 6 (2.7 6 0.2 versus 3.1 6 0.2 versus 4.2 6 0.4)
and, at week 1, lower clinical GVHD scores were par-
alleled by respective improvement in MV, PIF, and
PEF. All of the animals receiving 1 or 3million spleno-
cytes developedmild to moderate clinical symptoms of
GVHD, and none succumbed until day 142. Incontrast, allo-SCT with 6 million splenocytes resulted
in severe clinical disease and high mortality by this
time point (Figure 1). Also, 6 weeks after SCT, MV,
PIF, and PEF were decreased only in the latter group,
whereas they were not altered in allogeneic recipients
of 1 or 3 million splenocytes (Table 1), suggesting a
direct relation between clinical GVHD related illness
and changes in breathing patterns after allo-SCT.
Early clinical GVHD scores and mortality are pre-
dominantly driven by systemic inflammation because
of the overexpression of inflammatory cytokines such
as TNF or IFNg rather than by donor T cell infiltra-
tion into GVHD target organs, which plays a major
role during the cellular effector phase of GVHD later
on [28-30]. Therefore, we next analyzed histopatho-
logic changes in the GI tract, liver, and lung of synge-
neic and allogeneic recipients 1 and 6 weeks after SCT.
GVHD was induced by the infusion of either 1 or 6
million splenocytes at the time of transplantation.
Consistent with prior findings [31], conditioning tox-
icity, early alloreactive T cell expansion, and inflam-
matory cytokine production induced significant GI
tract injury early after allo-SCT, that declined by
week 6 (Table 2). In contrast, no significant injury to
the liver was observed by week 1, but was clearly evi-
dent by week 6 (Table 2). The lung demonstrated
moderate changes by week 11, and injury progressed
over time by week 16 (Table 2). Interestingly, the
severity of histopathologic damage did not differ
depending on the amount of allogeneic T cells being
administered. Therefore, it seems highly likely that
the susceptibility to individual mechanisms of the mul-
tipronged attack of post-SCT organ injury, including
conditioning toxicity, alloreactive T cell responses, lo-
cal cytokine production, NK cells, and others, differsTable 1. In Vivo Breathing Patterns Reflect Underlying GVHD-Induced Impairment of Physical Performance and Clinical Health
Week 1 Week 6
Splenocyte Dose 1  106 3  106 6  106 1  106 3  106 6  106
GVHD score syn 1.2 ± 0.2 1.4 ± 0.4 1.5 ± 0.2 0.5 ± 0.0 0.5 ± 0.0 1.0 ± 0.2
allo 2.8 ± 0.2† 3.5 ± 0.0† 4.0 ± 0.2† 2.7 ± 0.2† 3.1 ± 0.2† 4.2 ± 0.4†
RR syn 99.3 ± 1.8 102.2 ± 4.8 93.0 ± 1.8 87.2 ± 4.5 93.6 ± 5.1 81.9 ± 3.6
allo 94.2 ± 1.8 77.8 ± 4.0† 78.5 ± 2.5† 89.1 ± 2.5 91.5 ± 3.7 66.7 ± 3.4†
TV syn 103.7 ± 2.5 107.7 ± 5.3 101.1 ± 3.7 117.6 ± 5.4 106.1 ± 6.2 126.4 ± 3.4
allo 91.2 ± 1.9† 92.3 ± 2.1† 73.9 ± 1.7† 113.3 ± 6.0 112.7 ± 5.0 93.3 ± 4.9†
MV syn 102.1 ± 3.6 109.6 ± 8.9 92.7 ± 3.7 98.3 ± 2.7 96.4 ± 3.4 99.6 ± 3.8
allo 84.3 ± 1.3† 70.9 ± 4.1† 57.5 ± 2.3† 99.4 ± 5.4 100.4 ± 3 .1 61.5 ± 5.5†
PIF syn 110.1 ± 2.4 110.8 ± 5.3 102.8 ± 2.8 111.6 ± 2.3 106.2 ± 3.0 111.5 ± 3.0
allo 100.0 ± 1.1† 91.2 ± 2.5† 76.1 ± 2.5† 116.2 ± 5.1 116.0 ± 3.2 87.9 ± 5.2†
PEF syn 97.8 ± 4.3 108.3 ± 10.7 90.6 ± 4.5 91.9 ± 3.4 92.5 ± 4.0 90.2 ± 5.0
allo 77.2 ± 1.8† 69.3 ± 2.3† 56.3 ± 1.8† 96.3 ± 7.1 100.0 ± 4.0 58.8 ± 5.9†
Lethally irradiated B6D2F1mice were transplanted from syngeneic B6D2F1 or allogeneic C57BL/6 donors receiving 5 106 bonemarrow cells
and 1 106, 3 106, or 6 106 splenocytes. Clinical GVHD severity scores and respiratory patterns were measured on day17 and day142
as described inMaterials andMethods. The following parameters were assessed: minute ventilation (MV), tidal volume (TV), respiratory rate
(RR), peak inspiratory flow (PIF), and peak expiratory flow (PEF). For both syngeneic and allogeneic recipients, data shown are expressed as
% pre-SCT values. Data are presented as mean 6 SEM; n (syngeneic) 5 5-13 per group; n (allogeneic) 8-25 per group.
†P\ .01 comparing syngeneic versus allogeneic recipients at individual time points.
Lung Function Changes in Pulmonary GVHD 1011Table 2. GVHD Target Organ Injury to the GI Tract Precedes Hepatic and Pulmonary Graft- versus-Host Disease
Week 1 Week 6
Splenocyte Dose 1  106 6  106 1  106 6  106
Lung syngeneic 0 ± 0 0 ± 0 0.6 ± 0.4 0 ± 0
allogeneic 3.3 ± 0.7 2.4 ± 0.8 5.1 ± 0.4* 3.9 ± 0.4†
GI tract syngeneic 0.1 ± 0.1 0.2 ± 0.2 0.6 ± 0.4 1.1 ± 0.3
allogeneic 6.9 ± 0.8 8.8 ± 0.6 4.4 ± 0.5* 5.2 ± 0.5*
Liver syngeneic 0 ± 0 0 ± 0 0 ± 0 0 ± 0
allogeneic 0 ± 0 0 ± 0 2.0 ± 0.4* 3.0 ± 0.5*
GI indicates gastrointestinal; GVHD, graft-versus-host disease.
Lethally irradiated B6D2F1mice were transplanted from syngeneic B6D2F1 or allogeneic C57BL/6 donors receiving 5 106 bonemarrow cells
and 1  106 or 6  106 splenocytes. Histopathologic changes of the GI tract, liver, and lung were assessed 1 or 6 weeks after SCT. n (syn-
geneic): 4-11 per group; n (allogeneic): 6-16 per group.
*P\ .05.
†P 5 .05 comparing scores at week 1 with scores at week 6 of identically treated animals.between organs. Further, the clinical GVHD score
and changes in breathing patterns rather reflect the
sum of various independent factors than they can be at-
tributed to specific GHVD related target organ injury,
the latter specifically to the lung.
Changes in Vital Capacity, FEV, FEF, and
Compliance
We next characterized whether the histopathologic
changes observed in the lung after allo-SCT resulted in
restrictive or obstructive alterations of pulmonary
function because of intrinsic lung pathology. Restric-
tive lung injury was assessed by changes in VC, FVC,
and compliance (Cchord) on day17 and day142 after
SCTwith 5 x 106 bone marrow and 6 x 106 splenocytes.
At the same time points, changes in FEF and FEV weredetermined to test for air outflow obstruction and
animals. Measurements were performed using an anes-
thesized mouse PFT plethysmograph as described in
Materials and Methods, that, by applying passive venti-
lation to the sedated, nonself-breathing mouse, allows
the assessment of pulmonary function changes, specif-
ically lung volumes and flow measurements, which are
because of direct lung pathology and independent of
potentially confounding factors such as posture and
muscle strength. Pulmonary function values were
expressed in relation to naı¨ve animals, and were com-
pared between syngeneic and allogeneic groups.
FVC, VC, and Cchord in animals receiving syngeneic
SCT did not differ from untreated controls both 1
and 6 weeks after transplantation (Figure 4a-c). In con-
trast, allogeneic recipients showed significant decreasesFigure 4.Changes in compliance, lung volumes, and flow rates. (A-F) Lethally irradiated B6D2F1mice received SCTwith 5 106 bonemarrow
and 6  106 splenocytes from either syngeneic B6D2F1 or allogeneic C57Bl/6 donors, and on day17 and day142 PFT were performed as de-
scribed inMaterials andMethods. Lung injury was assessed by changes in (A) VC, (B) FVC, (C) Cchord, (D) FEV50, (E) FEV50/FVC, (F) FEF25.
The lowest, second lowest, middle, second highest, and highest box points represent the 10th percentile, 25th percentile, median, 75th percentile,
and 90th percentile, respectively. Means are represented by symbols. Data are presented as mean6 SEM and are combined from 2 independent
comparable experiments; week 1: n 5 7 to 10 per group, week 6: n 5 7 to 9 per group. *P\ .05, **P\ .01, 1P 5 .05.
1012 S. Miklos et al.Table 3. Changes in Lung Volumes and Flow Rates in Relation to Escalating Numbers of Allogeneic Donor T Cells
Week 1 Week 6
Splenocyte Dose 1  106 3  106 6  106 1  106 3  106 6  106
VC syn 107 ± 8.2 104 ± 4.6 99 ± 4.6 106 ± 5.7 106 ± 5.1 101 ± 2.8
allo 89 ± 4.9 90 ± 4.0‡ 81 ± 3.7† 101 ± 8.1 97 ± 6.0 86 ± 5.4‡
FVC syn 111 ± 11.6 104 ± 4.5 102 ± 6.6 108 ± 3.2 110 ± 5.1 104 ± 4.0
allo 92 ± 4.2 93 ± 4.4 83 ± 4.2* 101 ± 8.3 94 ± 9.4 88 ± 6.1
Cchord syn 107 ± 9.8 99 ± 9.4 100 ± 4.6 108 ± 6.6 113 ± 5.8 103 ± 4.3
allo 88 ± 5.5 88 ± 3.6 76 ± 4.5† 105 ± 9.8 102 ± 7.8 83 ± 6.4*
FEV50 syn 104 ± 9.5 99 ± 3.1 96 ± 5.1 101 ± 2.3 106 ± 4.0 98 ± 3.5
allo 86 ± 3.5 85 ± 7.4 80 ± 3.7* 88 ± 6.6 96 ± 4.2 76 ± 4.4†
FEV50/FVC syn 94 ± 1.5 96 ± 1.4 94 ± 1.3 94 ± 3.0 96 ± 1.1 95 ± 1.0
allo 94 ± 2.5 98 ± 0.6 97 ± 0.8 89 ± 7.3 90 ± 4.2 88 ± 5.1
FEF25 syn 109 ± 9.7 114 ± 6.5 87 ± 7.8 99 ± 15.6 84 ± 8.5 97 ± 2.3
allo 96 ± 9.2 107 ± 6.4 94 ± 5.4 75 ± 14.7 69 ± 11.6 62 ± 7.1†
FVC indicates forced vital capacity; VC, vital capacity.
Lethally irradiated B6D2F1mice were transplanted from syngeneic B6D2F1 or allogeneic C57BL/6 donors receiving 5 106 bonemarrow cells
and 1 106, 3 106, or 6 106 splenocytes. On day17 and day142 PFTwere performed as described inMaterials andMethods. Pulmonary
function impairment was assessed by changes in VC, FVC, Cchord, FEV50, FEV50/FVC, and FEF25. For both syngeneic and allogeneic re-
cipients, data shown are expressed as % of naive. Data are presented as mean6 SEM; n (syngeneic)5 4-8 per group; n (allogeneic) 5-10 per
group.
*P\ .05
†P\ .01
‡P 5 .05 comparing syngeneic versus allogeneic recipients at individual time points.of FVC and VC and a significant reduction in Cchord
as signs of restrictive lung function impairment as early
as 7 days after SCT and by week 6, although at the lat-
ter time point decreases in only VC and Cchord
reached statistical significance (Figure 4a-c).
We further analyzed, to which extent obstructive
changes in air outflow developed in these animals.
FEV50, a parameter of mouse pulmonary function test-
ing comparable to FEV1 used for the assessment of
pulmonary obstruction in human lung function test-
ing, stayed within normal limits after syngeneic SCT
when compared to untreated controls at 1 and 6 weeks
after SCT (Figure 4d). In contrast, allo-SCT resulted
in a significant drop of FEV50 both on day 17 and
on day 142 (Figure 4d). In subjects with restrictive
lung disease, FEV values can be lower than the
predicted normal values because of a reduction of vital
capacity volumes without the existence of real pulmo-
nary obstruction. Therefore, we determined FEV50/
FVC, a parameter that allows the assessment of air
outflow obstruction in the context of decreased FVC,
and FEF25, a parameter of obstructive changes in small
airways. As depicted in Figure 4e, FEV50/FVCwas not
reduced in allogeneic recipients 1 week after transplan-
tation, but showed a decreasing trend at day142 when
compared to syngeneic controls and to untreated ani-
mals. However, this difference did not reach statistical
significance (Figure 4e). Consistent with no changes in
FEV50/FVC7 days after SCT, FEF25 did not differ be-
tween syngeneic and allogeneic recipients at this time
point. However, FEF25 was significantly decreased
by week16, indicating a significant reduction in small
airway flow rates by week 16 because of obstruction(Figure 4f). Taken together, these findings demon-
strate that animals after allo-SCT developed severe
restrictive but not obstructive changes by week 1 after
transplantation, and that progressive inflammatory cell
infiltrates in the lungs were paralleled by combined
pulmonary restriction and the development of ob-
structive airway disease by week 6.
Using T cell titration experiments as described
above, we next reduced but did not eliminate clinical
aGVHD by infusing lower numbers of splenocytes (1
 106 and 3 106). Lung volumes and flow rates again
were assessed on day17 and day142, and none of the
transplanted animals died before either time point of
analysis (data not shown). Although statistically signif-
icant only in animals receiving 6  106 splenocytes,
early analysis on day17 revealed substantial decreases
in VC, FVC, and Cchord consistent with pulmonary
restriction in all 3 groups (Table 3). In contrast, at
week 6, significant changes of Cchord (P\ .05) and
VC (P 5 .05) could be detected only in those animals
receiving the highest dose of donor T cells. Decreases
in FEF25 and FEV50 at day142 also reached statistical
significance only in those animals that were given 6
million splenocytes, but reductions in FEF25 indicative
of obstructive small airway disease were clearly evident
in all groups.
Reduced SP-A Levels in the Lung after allo-SCT
SP-A is produced by alveolar epithelial type II cells
and, in addition to its antimicrobial function, it exerts
suppressive effects on dendritic cell maturation and
T cell proliferation [32-36]. Reduced SP-A levels
Lung Function Changes in Pulmonary GVHD 1013indicate an imbalance in surfactant regulation, and
have been associated with early pulmonary injury after
allo-SCT [37]. Therefore, we determined SP-A
expression in the lung at 1 and 6 weeks following syn-
geneic or allogeneic transplantation. As depicted in
Figure 5, SP-A expression in the lungs of allogeneic re-
cipients was significantly reduced in comparison to
syngeneic controls at both time points, suggesting,
that decreased SP-A levels and disturbed surfactant
balance contribute to restrictive pulmonary function
changes and promote subsequent lung injury mediated
by alloreactive T cells.
DISCUSSION
Beneficial effects of allo-SCT are counterbalanced
by high mortality because of serious complications
such as aGVHD and SCT-related injury to the lung.
Historically, the lung has not been considered as a tar-
get organ of aGVHD, and lung injury was assumedly
triggered by prior chemotherapy, conditioning
regimen toxicity, and occult infections. However, ex-
perimental data as well as clinical experience today
support the concept that the lung, in fact, is a critical
organ in post-SCT immunology, as it is prone to
injury by alloreactive donor immune responses [5,13-
20,38-40], leading to p-GVHD. p-GVHD can present
as interstitial und alveolar pneumonitis, perivascular
lymphocytic inflammation, or lymphocytic peribron-
chiolitis [3-8,23], and histologic changes can be closely
resembled in experimental models [14,15,17,20,21].
However, changes in pulmonary function have been
only sporadically addressed in these models, and in
vivo characterization of breathing patterns after allo-
SCT has been completely missing.
The purpose of our study was to analyze changes in
breathing parameters and pulmonary function after
transplantation by using a well-established murine
SCT model. In this system, development of pulmo-
nary pathology is dependent upon the infusion of allo-
geneic T cells along with the pretransplant radiation
dose and involves the recruitment of alloreactive
CD41 and CD81 T cells to the lung [13,17,41].
Figure 5. Reduced SP-A levels at 1 and 6 weeks after allo-SCT. (A-
B) SP-A levels in the lungs of syngeneic and allogeneic recipients of 5
 106 bone marrow and 6  106 splenocytes were determined at 1
and 6 weeks after transplantation as described in Materials and
Methods. Data are combined from 3 comparable experiments (day
7: n5 11 animals per group; day 42: n5 9 syngeneic and 11 alloge-
neic recipients) and presented as mean 6 SE. *P\ .05.Importantly, lung injury that develops in this model
is defined by several features that characterize human
disease including robust pulmonary infiltrates, in-
creased capillary permeability, and inflammatory cyto-
kine release [13,17].
Using this system, we chose 2 approaches to assess
how pulmonary physiology is affected after allo-SCT.
First, measurement of baseline breathing parameters
after transplantation was performed by whole-body
plethysmography. This method allowed us to evaluate
the living, unstressed animal in the absence of noninva-
sive or invasive ventilation, arranging for a setting that
simulates baseline respiratory function in the nonventi-
lated out- or inpatient subject after clinical SCT. An
extended follow-up until day 184 enabled us to better
assess how survival is affected by the development of
p-GVHD in a model, in which lung injury histologi-
cally has fully evolved by day 142 [17]. Our results
demonstrated that severe clinical distress because of
the development of aGVHD in allogeneic recipients
was mirrored by severe impairment of MV and peak
flows during inspiration and expiration. In clinical pa-
tients, beginning or manifest respiratory insufficiency
or other factors such as pain, fever, or stress, leads to
tachypnoeae in combination with decreased, normal,
or increased TVs to ensure sufficient MV and oxygen-
ation. However, in our study, allogeneic recipients dis-
played a significant decrease in both breathing
frequency andTV,most likely because of a combination
of aGVHD-related systemic weakness and changes in
air flow patterns. Inspiration as an active procedure of
diaphragm and respiratory muscles directly depends
on the ability to expand the lung against elastic recoil,
air flow resistance, and tissue resistance of lung and tho-
rax [42]. Expiration in the resting state and healthy lung
is exclusively a passive procedure mediated by the elas-
tic recoil of lung and thorax, but in the context of respi-
ratory distress is actively supported by respiratory
muscles. Therefore, our data suggest that animals after
allo-SCT in a severely reduced state of health are not
capable to maintain or increase baseline breathing fre-
quencies, TVs, and inspiratory or expiratory flow rates
to achieve compensation for a higher need of oxygen.
Instead, exertion of diaphragm and respiratory muscles
in combination with hunched posture and functional
restrictive and obstructive changes after allo-SCT cause
severe ventilation impairment, which is directly associ-
ated with increased mortality (Figure 3). Severely hin-
dered ventilation was directly associated with clinical
aGHVD severity, and partial recovery of ventilation pa-
rameters in surviving animals following week 18 post-
SCT along with decreased aGVHD scores reflects
a population bias caused by mortality of severely sick
animals and survival of less sick animals, respectively.
An initial drop inMVwas also seen in animals after
syngeneic SCT, which can be explained by the effects
of conditioning toxicity on general strength and health
1014 S. Miklos et al.in these animals. In contrast to allogeneic recipients,
however, reduced ventilation after syngeneic SCT
was not associated with any mortality.
In a second approach, we evaluated compliance as
well as static and dynamic lung volumes as indicators
of restrictive or obstructive pulmonary function
changes after SCT. Command-controlled test proce-
dures cannot be performed in mice as they can in hu-
mans. Therefore, the underlying technique involves
passive ventilation of the sedated, not spontaneously
breathing animal in combination with a high-end ple-
thysmograph, and, in contrast to our first approach,
parameters obtained do not depend on active breath-
ing maneuvers of the transplanted animal and directly
reflect intrinsic lung pathology. Both static lung
volumes including VC, FVC, and compliance were
not affected in syngeneic recipients. Also, no pulmo-
nary obstruction developed in these animals. In con-
trast, transplantation of allogeneic T cells led to
significant pulmonary restriction as early as 1 week
after SCT. These findings are comparable to results
obtained by using a different mouse model of lung
injury after allo-SCT, when a reduction of total lung
capacity [14,24] and compliance [14,25,26] were
observed around the same time along with interstitial
thickening and mild to moderate perivascular inflam-
matory cell infiltrates [14]. Respective histopathologic
changes early after allogeneic SCT were seen in our
study in about one-third of animals, whereas restrictive
pulmonary function changes were found in .80% of
these animals, suggesting that impaired pulmonary
function may reflect early histologic changes that can-
not yet be identified by light microscopy [14] and pre-
cede obvious pulmonary inflammation. Further, at this
point it is still unclear whether histology and lung
function changes seen this early after allo-SCT in
both models indeed present acute noninfectious inter-
stitial pneumonitis after allo-SCT, historically defined
as early IPS [4] as they could alsomirror PERDS or the
effects of conditioning toxicity in close interplay with
alloreactive T cell expansion in secondary lymphoid
organs and systemic inflammation [30,41]. TNF:TNF
receptor type I (TNFRI) interactions have proved to
be critical in the development of aGVHD and early
mortality after allo-SCT [30,31,43]. Shukla and col-
leagues [25] recently demonstrated that interrupting
TNF:TNFRI signaling in allo-SCT recipients re-
sulted in improved early post-SCT survival that was
associated with decreased pulmonary edema and im-
proved lung compliance on day 7 after SCT. In the
same animals, however, cellular infiltration into the
lung as a classical characteristic of IPS was actually
stronger than that seen in those allogeneic recipients,
in which TNF:TNFRI signaling was intact along
with increased pulmonary edema and higher mortality
[25]. This suggests that the observed lung injury at 1
week after transplantation may rather resemble acutedisturbances in endothelial and epithelial barrier func-
tion, similar to those seen in PERDS or triggered by
systemic inflammation, and does not necessarily reflect
cellular pneumonitis. Decreased SP-A levels early after
allo-SCT may, however, promote the development of
alloreactive T cell-mediated injury to the lung because
of a lack of its suppressive effects on dendritic cell mat-
uration and T cell proliferation [32-36].
In our study, restrictive pulmonary function
changes at week 11 after allo-SCT occurred in recip-
ients of low, medium, and high numbers of donor T
cells, and although a statistical significance was only
shown for those animals receiving the highest T cell
dose, reductions in VC, FVC, andCchord in all groups
but not in syngeneic controls demonstrate that the de-
velopment of early pulmonary restriction is at least
partially T cell dependent and involves critically co-
contributing lung-alloantigen-independent factors,
for example, radiation-mediated endothelial and epi-
thelial injury and systemic cytokine expression.
Parallel to the development of parenchymal pneu-
monitis and of periluminal lung infiltrates around
airways and vessels, progressive air outflow obstruc-
tion in addition to restrictive pulmonary function
changes occurred in surviving allogeneic recipients
by week 6. The development of restriction 6 weeks af-
ter allo-SCT was directly related to the T cell dose, as
significant restrictive changes of pulmonary function
occurred only in animals receiving the highest number
of splenocytes. Obstructive pulmonary function
changes also seemed T cell dose dependent, as reduc-
tions in FEF25 and FEV50 only reached significance
with the highest dose of T cells given, but were also
detectable in those groups treated with low or medium
numbers of donor splenocytes and in the absence of
GVHD-related mortality. Panoskaltsis et al. [44] re-
cently described a murine model, in which obstructive
pulmonary changes occurred around 2 months after
allo-SCT, accompanied by periluminal donor cell
infiltrates and by histologically proved obliterative
bronchiolitis in a minority of animals. Therefore, lym-
phocytic peribronchiolitis plus air outflow obstruction
in our study likely present a form of p-GVHD, that in
some cases gives rise to the development of bronchial
luminal obliteration, whereas manifest alveolar and
interstitial cell infiltrates along with inflammatory cy-
tokine expression [12,13,16,17] resemble classical
IPS as an acute form of p-GVHD, leading to increased
mortality.
In summary, our data demonstrate a close correla-
tion between the development of clinical GVHD,
p-GVHD, and impaired ventilation after allo-SCT.
Respiratory dysfunction, because of both alloim-
mune-mediated injury to the lung and because of
aGVHD-related reductions in the general state of
health, are directly associated with increasedmortality,
emphasizing the lung as a critical GVHD target organ
Lung Function Changes in Pulmonary GVHD 1015in SCT immunology. Further, in addition to histopa-
thology, BALF cellularity and cytokine expression,
pulmonary function testing in experimental models
of p-GVHD provides a powerful tool to assess the se-
verity of lung injury, as it directly provides important
information on p-GVHD-related clinical and patho-
physiologic ramifications, and may be additionally
used to monitor the effectiveness of experimental
therapeutic approaches.
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